Posted by Michael Wonder on 30 Mar 2022
Enanta Pharmaceuticals receives FDA fast track designation for EDP-235, its oral 3CL protease inhibitor specifically designed for the treatment and prevention of COVID-19
29 March 2022 - Enanta Pharmaceuticals today announced that the U.S. FDA has granted fast track designation for EDP-235, its coronavirus 3CL protease inhibitor specifically designed as a once-daily, oral treatment for COVID-19.
Currently, EDP-235 is in a first-in-human Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of oral EDP-235 in single ascending doses, including a two part food effect cohort, and multiple ascending doses, compared to placebo in healthy volunteers.
